The Cure Parkinson's Trust

What The Cure Parkinson's Trust does

The Cure Parkinson's Trust is a UK-registered charity (England and Wales no. 1111816; Scotland no. SCO44368), founded in 2005 by four people living with Parkinson's, that exists solely to fund research aimed at slowing, stopping, or reversing the disease. Its operational core is the International Linked Clinical Trials (iLCT) programme, co-led with the Van Andel Institute since 2012, in which 20-plus world-leading Parkinson's experts convene annually to evaluate and rank 15–20 drug dossiers for clinical-trial prioritization. As of March 2025, 31% of all Parkinson's disease-modifying drugs in active clinical trials worldwide had been evaluated through iLCT; the charity has directly committed over £25.5 million across 86-plus research projects at 41 institutions in 12 countries and facilitated more than £100 million in additional external funding.

The organization's product surface consists of research-grant programmes (Quarterly Research Grant Funding Programme, iLCT Pipeline Research Acceleration Programme), the multi-arm EJS ACT-PD clinical trial platform testing repurposed therapies, and a community-and-education layer including the 26,000-user Health Unlocked forum, the Cure InSight newsletter, quarterly webinars with the University of Edinburgh and the Journal of Parkinson's Disease, and the Rallying to the Challenge annual meeting. Revenue is generated entirely through charitable streams — individual donations, legacies and gifts in wills, corporate partnerships, trust and foundation grants (e.g., Frank Brake Charitable Trust since 2006), major gifts via the Cure Collective, and event fundraising — with no commercial product sales. Cure Parkinson's operates under a board of trustees and a senior leadership team led by CEO Helen Matthews, with research and clinical leadership provided by Director of Research Dr Simon Stott and Director of Clinical Development Dr Richard Wyse MBE.

Name

The Cure Parkinson's Trust

Legal name

The Cure Parkinson's Trust

Website

https://cureparkinsons.org.uk

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

11–50 employees

Short description

The Cure Parkinson's Trust is a UK-registered charity funding research to slow, stop, or reverse Parkinson's disease through its co-led International Linked Clinical Trials (iLCT) drug-prioritization programme, research grants, and community engagement for people with Parkinson's, researchers, and donors worldwide.

Ownership category

akta.pro rank

Product category

Medical Research Charity

NAICS

Voluntary Health Organizations (813212), Grantmaking and Giving Services (81321)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Health & Medical Research Grantmaking Foundations (BPAGAKAL)

akta.pro secondary industries

Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS) (BPAGACAA), Research & Science Grantmaking Foundations (BPAGAKAI)

Keywords

• Parkinson's research funding
• Disease-modifying therapies
• Clinical trials programme
• Medical research charity
• Preclinical research grants

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Others, Personnel, Operations

Revenue model

1. Individual Donations: One-time and regular donations from individual supporters, including monthly direct debits. Donations can be made online, by post, or over the phone.
2. Legacies and Gifts in Wills: Bequests and legacy gifts left by supporters in their Wills to fund future Parkinson's research.
3. Corporate Partnerships: Companies partner with Cure Parkinson's through charity of the year programmes, fundraising events, corporate challenges, sponsored events, cause-related marketing, and matched giving schemes.
4. Trust and Foundation Grants: Trusts and foundations provide funding for specific research projects or general research initiatives. Partners include Frank Brake Charitable Trust and others providing multi-year funding.
5. Major Gifts: Philanthropic individuals make significant donations, with options to join the Cure Collective giving circle for annual or monthly commitments.
6. Event Fundraising: Supporters participate in organized events including marathons, cycling challenges, walks, skydives, gala evenings, and community events, raising funds for the charity.

Go-to-market motion1 record

Distribution channels6 records

Marketing channels8 records

Core offering

The Cure Parkinson's Trust is a UK-registered charity that funds and supports preclinical and clinical research aimed at slowing, stopping, or reversing the progression of Parkinson's disease. Its core activity centres on grant-making (Quarterly Research Grants, iLCT Pipeline Research Acceleration Programme) and the proprietary International Linked Clinical Trials (iLCT) drug prioritization programme run in partnership with Van Andel Institute. The charity also engages the Parkinson's community through educational events, clinical trial recruitment, and the Health Unlocked forum.

Product overview

The Cure Parkinson’s Trust is a UK-based charity focused exclusively on funding research to slow, stop, or reverse Parkinson’ disease. The organization does not offer a technology product in the traditional sense, but operates several research programs and community engagement initiatives. Core offerings include the International Linked Clinical Trials (iLCT) Programme (in partnership with Van Andel Institute) which evaluates and prioritises disease-modifying drug treatments, the Quarterly Research Grant Funding Programme for preclinical and clinical research, and the iLCT Pipeline Research Acceleration Programme. Supporting programs include the EJS ACT-PD clinical trial platform, educational events (Rallying to the Challenge, Research Update Meetings, webinars), the Health Unlocked community forum, and the Cure InSight newsletter.

Differentiator

Problem solved

Functional benefit

Products and services

• International Linked Clinical Trials (iLCT) Programme A global drug prioritisation programme that brings together over 20 world-leading Parkinson's experts annually to evaluate 15-20 drug dossiers and rank candidates for clinical testing priority. Between 2012 and 2024, 239 dossiers representing 171 unique agents have been reviewed, and 31% of all Parkinson's disease-modifying drugs in active clinical trials worldwide have been evaluated by the iLCT committee.
• Quarterly Research Grant Funding Programme Preclinical and clinical research funding programme focused on disease modification to slow, stop, or reverse Parkinson's. Prioritises projects that could lead to clinical trials within 5 years. Accepts applications from academics and commercial entities internationally.
• iLCT Pipeline Research Acceleration Programme Funds research outlined by the iLCT committee as necessary before a therapy can move into clinical trials, including preclinical, epidemiological, dose finding or target engagement research.
• EJS ACT-PD Clinical Trial Platform The Edmond J Safra Accelerating Clinical Trials for Parkinson's Disease (EJS ACT-PD) multi-arm, multi-stage (MAMS) trial platform, allowing testing of multiple treatments (telmisartan, terazosin, UDCA) against a shared placebo group.
• Health Unlocked Community Forum Online discussion forum with over 26,000 users for people affected by Parkinson's to connect, share experiences, and discuss research and life with the condition.
• Cure Parkinson's Webinar Series Quarterly webinars held in partnership with the University of Edinburgh and the Journal of Parkinson's Disease, covering the latest innovations in Parkinson's research with clinicians, researchers, industry experts and people with Parkinson's.

Quantifiable outcome

• Over £25.5 million of direct funding committed; £100 million+ external funding facilitated
• +4 more outcomes

Named customers3 records

Segments6 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

15 partnerships are on record, tiered core, major and minor.

• Van Andel Institute (VAI)coreStrategic or Co-development Partner · 1 January 2012Strategic partnership to co-lead the International Linked Clinical Trials (iLCT) programme. VAI is an independent non-profit biomedical research and science education organisation based in Grand Rapids, Michigan. The annual iLCT committee meeting is hosted jointly by Cure Parkinson's and VAI, bringing together over 20 world-leading Parkinson's experts to evaluate and prioritize potentially disease-modifying treatments for clinical trials.
• John Black Charitable Foundation (JBCF)coreStrategic or Co-development PartnerStrategic funding partner for the iLCT initiative. JBCF was established for the advancement of health and the relief of sickness, particularly prostate cancer and Parkinson's disease. Provides essential funding alongside Cure Parkinson's and Van Andel Institute for the global drug prioritization programme.
• The Michael J. Fox FoundationmajorStrategic or Co-development PartnerCollaboration on Fox Trial Finder and shared support for Parkinson's research. Joint efforts to expand clinical trial recruitment and fund promising Parkinson's research initiatives.
• Parkinson's UKmajorStrategic or Co-development PartnerRegular collaboration on both funding Parkinson's research and activities to raise awareness of the condition. Works together on shared objectives in the UK Parkinson's community.
• Garvan Institute / Australian Parkinson's MissionmajorStrategic or Co-development PartnerPartnership with the Garvan Institute for the Australian Parkinson's Mission, the largest clinical research programme for Parkinson's in Australia. An innovative research programme combining clinical trials with genomics research.
• Critical Path for Parkinson's Consortium (CPP)minorStrategic or Co-development PartnerNon-voting member of the consortium launched in 2015. A global collaboration that aims to pave the path to new treatments for Parkinson's through regulatory science and clinical trial innovation.
• The Neurological AllianceminorStrategic or Co-development PartnerMember of the Neurological Alliance, a group of 80 organisations working together to make life better for people in England with neurological conditions.
• The Pistoia AllianceminorStrategic or Co-development PartnerMember of the Pistoia Alliance for non-competitive data collection and sharing, particularly around genetics, and innovative thinking around clinical trials and outcomes.
• Parkinson's AcademyminorStrategic or Co-development PartnerPartner of the Parkinson's Academy, an innovative education provider for clinicians, specialist nurses and professions allied to medicine working in Parkinson's care or research.
• PD AvengersminorStrategic or Co-development PartnerWorks with PD Avengers, a global alliance of people connected to Parkinson's standing together to demand change in how the disease is seen and treated. Supports the Sparks of Experience initiative.
• World Parkinson Coalition (WPC)majorStrategic or Co-development PartnerWorks closely with the WPC, a non-profit providing an international forum for scientific discoveries, medical practices, caregiver initiatives and advocacy related to Parkinson's.
• University of EdinburghmajorStrategic or Co-development PartnerPartnership for quarterly webinars with the Journal of Parkinson's Disease. Professor Tilo Kunath from University of Edinburgh chairs the webinar series featuring clinicians, researchers, industry experts, and people with Parkinson's.
• Journal of Parkinson's DiseasemajorStrategic or Co-development PartnerPartner for regular webinar series. The journal is dedicated to providing an open forum for original research in basic science, translational research, and clinical medicine related to Parkinson's disease.
• Association of Medical Research Charities (AMRC)minorOthersMember of AMRC. Follows their recommendations for best practice in research. Received certificate of best practice in peer review audit. AMRC principles include accountability, balance, independent decision making, rotation of scientific advisers and impartiality.
• PD Trial Tracker.InfominorStrategic or Co-development PartnerPartnership to provide analysis of ongoing Parkinson's clinical trials and observational studies worldwide, helping patients, families, researchers and healthcare providers understand the trial landscape.

Scale indicators13 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• The Michael J. Fox Foundation for Parkinson's Research: The largest dedicated Parkinson's research funder globally, similarly focused on accelerating disease-modifying therapies. Directly comparable as a charitable grantmaker for Parkinson's research, with overlapping research priorities and shared partnerships.
• Van Andel Institute: Co-leads the iLCT programme with Cure Parkinson's and runs Parkinson's-dedicated research programmes. Directly comparable as a research-focused partner/peer focused on disease modification.
• Aligning Science Across Parkinson's (ASAP): A coordinated research initiative supporting collaborative, milestone-driven Parkinson's research. Comparable as a Parkinson's-specific research funding coalition with a similar disease-modification focus.
• Critical Path for Parkinson's (CPP) Consortium: A global collaboration focused on Parkinson's clinical trial innovation and regulatory science. Already a listed partner of Cure Parkinson's, with overlapping mission to accelerate Parkinson's therapeutic development.
• Davis Phinney Foundation: A US Parkinson's-focused nonprofit funding research and supporting people with Parkinson's. Comparable as a disease-specific research and quality-of-life funder.

Broad incumbents

• Parkinson's UK: The UK's largest Parkinson's charity, with a broader remit spanning support, information, and research. While also a major research funder, its wider service mission places it as a broad incumbent rather than a cure-specific peer.
• American Parkinson Disease Association: US-based Parkinson's charity funding research and providing patient services. Comparable as a Parkinson's-specific funder with both research and broader mission elements.

Emerging players

• Shake It Off Foundation: A smaller Parkinson's research fundraiser focused on disease-modifying therapies. Comparable mission but at a more modest scale than Cure Parkinson's.

Regional players

• Garvan Institute / Australian Parkinson's Mission: Australia's largest Parkinson's clinical research programme, combining genomics and trials. Already a strategic partner; comparable as a Parkinson's-specific research programme operating in a different geography.

Others

• Journal of Parkinson's Disease: An academic publication dedicated to Parkinson's research. While not a research funder, it is a content partner for Cure Parkinson's webinar series and provides overlapping reach into the research community.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/cureparkinsonsT
• Facebookfacebook.com/cureparkinsons
• LinkedInlinkedin.com/company/cure-parkinsons

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Cure Parkinson's Trust